Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14156407 | 1.00 | TAS1R3 (0.33) | TAS1R3TAS1R1MAPTCA1CA2 | |
| SCHEMBL8047930 | 0.84 | MAPT (0.35) | TAS1R3TAS1R1MAPTCA1CA2 | |
| SCHEMBL14156214 | 0.84 | MAPT (0.35) | TAS1R3TAS1R1MAPTCA1CA2 | |
| SCHEMBL11861641 | 0.81 | TAS1R3 (0.36) | TAS1R3TAS1R1CA1CA2DGAT1 | |
| SCHEMBL14266016 | 0.79 | TET2 (0.36) | — | |
| SCHEMBL14587071 | 0.79 | TET2 (0.36) | — | |
| SCHEMBL12813107 | 0.78 | TAS1R3 (0.35) | TAS1R3TAS1R1CA1CA2DGAT1 | |
| SCHEMBL10098425 | 0.78 | MMP8 (0.42) | TAS1R3TAS1R1CA1CA2DGAT1 | |
| SCHEMBL12665739 | 0.76 | MMP8 (0.34) | TAS1R3TAS1R1CA1CA2DGAT1 | |
| SCHEMBL10297997 | 0.76 | MMP8 (0.34) | TAS1R3TAS1R1CA1CA2DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902218-B2 | Inhibit production of A beta -peptide; neurological disorders, Alzheimer's disease; (S)-2-((S)-3-Acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)propan-2-yl)-4-phenylbutanamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-7557137-B2 | Gamma-lactams as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20080153868-A1 | Substituted Tetrahydroisoquinolines as Beta-secretase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-20070265331-A1 | Novel gamma-lactams as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153868-A1 | Substituted Tetrahydroisoquinolines as Beta-secretase Inhibitors | BACE1, APP, BACE2 | TAS1R3 2306/4885TAS1R1 1890/4885MAPT 62/4885 |
| US-20070265331-A1 | Novel gamma-lactams as beta-secretase inhibitors | BACE1, APP, BACE2 | TAS1R3 2939/4885TAS1R1 2289/4885MAPT 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.